Endo International has acquired exclusive US and Mexican rights to Trimel BioPharma’s Natesto testosterone nasal gel, which was approved by the the FDA in May 2014 as a replacement treatment for men with low levels of endogenous testosterone. Endo is paying $25 million up front plus potential milestone payments.
In addition, Endo will manufacture and supply the product and pay a tiered supply price, the company said. Both companies will work together on further development and regulatory activities.
Endo President and CEO Rajiv De Silva commented, “We are pleased to acquire the rights to Natesto to further enhance our branded pharmaceutical portfolio and look forward to leveraging our commercial expertise in the areas of men’s health and urology to support this highly differentiated product. Natesto offers a unique intranasal delivery system which will expand options for appropriate patients seeking testosterone replacement therapy and we are focused on getting Natesto to market as expeditiously as possible.”
Trimel is also developing an intranasal testosterone product called Tefina for the treatment of anorgasmia in women, and the company recently launched a new website seeking partnerships for its Trivair dry powder inhaler for either pulmonary or intranasal delivery.
Read the Endo press release.
